Specifications of all patients with slight progression N = 48 | PFS-HR (95% CI) | p | OS-HR (95% CI) | p |
Age | 1.047 (1.008–1.089) | 0.019 | 1.025 (0.982–1.069) | 0.265 |
Number of metastatic organs | 1.159 (0.873–1.538) | 0.307 | 1.107 (0.820–1.494) | 0.508 |
PFS-HR (95% CI) | p | OS-HR (95% CI) | p | |
Gender | ||||
man/woman | 3.202 (1.473–6.962) | 0.003 | 2.077 (0.891–4.846) | 0.091 |
MSKCC score | ||||
0 / 1 / 2 | 1 / 3.671 (0.474–28.414) / 5.304 (0.709–39.661) | 0.176 | 1 / 2.965 (0.375–23.430) / 3.841 (0.513–28.786) | 0.366 |
Dose reduction | ||||
Yes / No | 1 / 0.840 (0.450–1.570) | 0.585 | 1 / 0.724 (0.365–1.436) | 0.356 |
Nephrectomy | ||||
Yes / No | 1 / 3.397 (1.364–8.461) | 0.009 | 1 / 5.583 (2.135–14.601) | < 0.001 |
Dose escalation | ||||
Yes / No | 1 / 2.383 (1.241–4.578) | 0.009 | 1 / 2.479 (1.185–5.183) | 0.016 |
Dose scheme modification | ||||
Yes / No | 1 / 2.373 (1.034–5.445) | 0.041 | 1 / 2.583 (1.008–6.709) | 0.047 |
Therapeutic lines after sunitinib | ||||
2 / 1 / 0 | NA | NA | 1 / 6.163 (1.582–24.016) / 3.873 (1.130–13.280) | 0.032 |